Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™

TORONTO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the Company’s first indication-specific drug registration for Trunerox™ issued by INVIMA, the Health Authority of Colombia.

Read more at globenewswire.com